SNY Sanofi

By Inti Landauro

PARIS-- French pharmaceutical group Sanofi SA (SAN.FR) said it plans to file for registration of its dengue vaccine in 2015 in several countries where the disease is endemic after the publication of results of the final clinical study in Latin America.

The company said the vaccine's overall efficacy against any symptomatic dengue disease was 60.8% in children and adolescents, while analyses showed a 95.5% protection against severe dengue and an 80.3% reduction in the risk of hospitalization during the study.

Sanofi said the world's first dengue vaccine could be available in the second half of 2015.

Dengue is a disease transmitted by mosquitoes that is endemic in parts of Asia and Latin America and is expanding geographically. About 550,000 people are hospitalized every year due to severe dengue. The disease can develop in a hemorrhagic fever that can be deadly. Sanofi says dengue is a threat for 2.5 billion people.

-Write to Inti Landauro at inti.landauro@wsj.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires